Global Blood Therapeutics’ sickle cell disease medicine Oxbryta got off to a hot start after a November FDA approval. But early in its launch, execs now say they’re seeing a “clear headwind” from the COVID-19 pandemic. Lately, new patient starts have
read moreSince 2015, federal authorities have been investigating bribery allegations against Alexion Pharmaceuticals in several countries. That process could finally be nearing an end under a newly disclosed settlement proposal. More: Five years later, Alexion sets aside M to resolve SEC's foreign
read moreBristol Myers Squibb CEO Giovanni Caforio credited COVID-19-related stocking for high sales of some products in the first quarter, including Eliquis, a blood thinner that’s being snapped up to reduce clotting risk in patients with the virus. But the pandemic
read moreBiogen has had a rocky road with its controversial Alzheimer’s disease candidate aducanumab, resurrected late last year. But despite postponing the drug’s FDA filing half a year, Biogen is still moving forward with plans to scale up production if aducanumab
read moreGlaxoSmithKline has offloaded a chunk of its consumer health business in a deal that earned the company more proceeds than expected. On Thursday, GSK said it sold its entire 5.7% stake in Unilever’s Indian business, known as Hindustan Unilever, for
read moreDr Mike England joins as medical director for UK & ROI More: Merck names Doina Ionescu as UK and Ireland general manager Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals